Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

Recruiting now

Conditions studied: Pancreas Cancer

In brief

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Key facts

Study ID

NCT04616131

Run by

Northwestern University

People needed

500

Starts

2020-10-01

Expected to finish

2029-10-01

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy or cytology proven adenocarcinoma of the pancreas
• No clinical evidence of metastatic disease on imaging
• Age 18 or older
• Receiving chemotherapy for non-metastatic pancreatic cancer

You may not qualify if…

• Biopsy proven metastatic disease

Where it is running

• Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois, United States (enrolling)
• Northwestern Medicine Cancer Center Delnor — Geneva, Illinois, United States (enrolling)
• Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.